Results 191 to 200 of about 21,818 (334)
CRISPR/Cas9-Mediated Development of Potato Varieties with Long-Term Cold Storage and Bruising Resistance. [PDF]
Massa GA +7 more
europepmc +1 more source
Sweetening the Deal: Glycosylation and its Clinical Applications
Yichi Zhang, Lichun Sun
openalex +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Low- or No-Energy Sweeteners and Body Weight Management: Dissecting a "Minor" Effect. [PDF]
Bellisle F.
europepmc +1 more source
Identification of Mango Key Sweetening Aromas and Decoding of Their Odor-Taste Association
Yiqing Ge, Qian Wang, Jihong Wu, Fei Lao
openalex +1 more source
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
Natural sweetening of food products by engineering Lactococcus lactis for glucose production
Wietske A. Pool +4 more
openalex +2 more sources
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source

